Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI-Based Cancer Diagnosis System Eliminates Errors

By LabMedica International staff writers
Posted on 25 Apr 2018
The first-ever artificial intelligence (AI)-based digital pathology diagnostic system has been deployed in a live clinical setting, following a pilot period, in which the system identified isolated major errors in retrospective prostate core needle biopsies (PCNBs) that had been diagnosed as benign.

The Second Read (SR) system, developed by Ibex Medical Analytics (Tel Aviv, Israel), a developer of AI-powered cancer diagnostics, has been deployed at the pathology institute of Maccabi Healthcare Services, which is among the largest healthcare providers in Israel and is also the company’s strategic partner. More...
The lab is a centralized pathology institute that handles 160,000 histology accessions per year, out of which approximately 700 are PCNBs.

Ibex develops AI-driven clinical decision support tools that help pathologists deliver more efficient, metric-driven, objective and accurate diagnosis. The company combines AI, data science, image analysis and machine learning technologies and applies them to cancer diagnostics in digital pathology. The SR system is software that identifies various cell types and features within whole slide images of PCNBs, including grading of cancerous glands and other clinically significant features. Ibex's algorithm utilizes state-of-the-art AI and machine learning techniques, and has been trained on thousands of image samples taken from hundreds of PCNBs from multiple institutes.

"We are excited to be the first company to ever deploy an AI-based system in a clinically-active pathology lab, leveraging the enormous potential of AI to make a real impact on human lives. We are now putting our full focus on making this system commercially available," stated Joseph Mossel, CEO and Co-founder of Ibex Medical Analytics.

"The complexity of prostate cancer diagnosis, together with the considerable shortage of pathologists, makes a second read system like this extremely useful for diagnostic accuracy and safety," said Dr. Judith Sandbank, Head of the Maccabi pathology institute and Chief Medical Officer at Ibex Medical Analytics.

Related Links:
Ibex Medical Analytics


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.